VCU-1012

VCU-1012(compound 15) (0.1, 0.5, or 1 mg/kg; i.p.; single administration) dose-dependently induces head-twitch response (HTR) in adult male C57BL/6J mice. The response peaks within the first 15 min post-administration and persists for more than 45 min; 0.5 and 1 mg/kg significantly increase the cumulative HTR within the first 30 min^[1].
VCU-1012 (1 mg/kg; i.p.; 24 h after a single administration) reduces immobility time in the forced swim test of WT mice, but exerts no such effect in 5-HT2AR KO mice; it does not significantly alter spontaneous horizontal activity or the time spent in the central area of the open field in WT mice during the same period^[1].
VCU-1012 (1 mg/kg; i.p.; administered on day 15 after the final dose of Paclitaxel, with tests conducted 24 h later) abolishes the light-avoiding phenotype observed in Paclitaxel (HY-B0015)-treated mice in the light-dark box test; administration of VCU-1012 alone does not alter anxiety-like behaviors, and no significant changes are observed in the number of light-dark box crossings among all groups^[1].
VCU-1012 (1 mg/kg; i.p.; 24 h after a single administration) increases the total dendritic spine density and mature mushroom-shaped dendritic spine density in the prefrontal cortex of WT mice, with an effect comparable to that of psilocybin; VCU-1012 does not significantly alter stubby or thin spines, and the increases in total dendritic spines and mushroom-shaped dendritic spines are abolished in 5-HT2AR KO mice^[1].
VCU-1012 (1 mg/kg; i.p.; single administration) does not significantly alter charcoal meal propulsion in the small intestine of mice, whereas Quipazine (HY-W028142) (5 mg/kg; i.p.) significantly inhibits small intestinal propulsion^[1].